Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 13/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16841384 | 1.00 | PTGER4 (0.50) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15586937 | 0.76 | PTGER4 (0.41) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16408740 | 0.76 | PTGER4 (0.41) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL17487079 | 0.74 | PTGER4 (0.48) | PTGER4PTGER2PTGER3 | |
| SCHEMBL17548575 | 0.74 | PTGER4 (0.48) | PTGER4PTGER2PTGER3 | |
| SCHEMBL16819470 | 0.67 | PTGER4 (1.00) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL19328437 | 0.67 | PTGER4 (1.00) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL16819525 | 0.65 | PTGER4 (0.77) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL18123936 | 0.65 | PTGER4 (0.76) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL18133252 | 0.57 | PTGER4 (0.35) | PTGER4PTGER2PTGER3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | MYOMETRICS, LLC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9701630-B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170066751-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160340306-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2016-11-24 | — | — | US | disclosed |
| US-9487478-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9440919-B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160158413-A1 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160024006-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9180116-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20150174099-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 5/4885PTGER3 3/4885 |
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 5/4885PTGER3 4/4885 |
| US-20160024006-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20160340306-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 5/4885PTGER3 3/4885 |
| US-20170066751-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.